Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.

Functional inactivation of wild-type p53 is a major trait of cancerous cells. In many cases, such inactivation occurs by either TP53 gene mutations or due to overexpression of p53 binding partners. This review focuses on an overexpressed p53 binding partner called mortalin, a mitochondrial heat shock protein that sequesters both wild-type and mutant p53 in malignant cells due to changes in subcellular localization. Clinical evidence suggests a drastic depletion of the overall survival time of cancer patients with high mortalin expression. Therefore, mortalin-p53 sequestration inhibitors could be game changers in improving overall survival rates. This review explores the consequences of mortalin overexpression and challenges, status and strategies for accelerating drug discovery to suppress mortalin-p53 sequestration.

A critical review on antiviral peptides derived from viral glycoproteins and host receptors to decoy herpes simplex virus.

The health of the human population has been continuously challenged by viral infections. Herpes simplex virus (HSV) is one of the common causes of illness and can lead to death in immunocompromised patients. Existing anti-HSV therapies are not completely successful in eliminating the infection due to anti-viral drug resistance, ineffectiveness against the latent virus and high toxicity over prolonged use. There is a need to update our knowledge of the current challenges faced in anti-HSV therapeutics and realize the necessity of developing alternative treatment approaches. Protein therapeutics are now being explored as a novel approach due to their high specificity and low toxicity. This review highlights the significance of HSV viral glycoproteins and host receptors in the pathogenesis of HSV infection. Proteins or peptides derived from HSV glycoproteins gC, gB, gD, gH and host cell receptors (HSPG, nectin and HVEM) that act as decoys to inhibit HSV attachment, entry, or fusion have been discussed. Few researchers have tried to improve the efficacy and stability of the identified peptides by modifying them using a peptidomimetic approach. With these efforts, we think developing an alternative treatment option for immunocompromised patients and drug-resistant organisms is not far off.

Cascading Beta-oxidation Intermediates for the Polyhydroxyalkanoate Copolymer Biosynthesis by Metabolic Flux using Co-substrates and Inhibitors.

Polyhydroxyalkanoates (PHAs) are biopolymers that are produced within the microbial cells in the presence of excess carbon and nutrient limitation. Different strategies have been studied to increase the quality and quantity of this biopolymer which in turn can be utilized as biodegradable polymers replacing conventional petrochemical plastics. In the present study, Bacillus endophyticus, a gram-positive PHA-producing bacterium, was cultivated in the presence of fatty acids along with beta-oxidation inhibitor acrylic acid. A novel approach for incorporating different hydroxyacyl groups provided using fatty acids as co-substrate and beta-oxidation inhibitors to direct the intermediates to co-polymer synthesis was experimented. It was observed that higher fatty acids and inhibitors had a greater influence on PHA production. The addition of acrylic acid along with propionic acid had a positive impact, giving 56.49% of PHA along with sucrose which was 1.2-fold more than the control devoid of fatty acids and inhibitors. Along with the copolymer production, the possible PHA pathway functional leading to the copolymer biosynthesis was hypothetically interpreted in this study. The obtained PHA was analyzed by FTIR and 1H NMR to confirm the copolymer production, which indicated the presence of poly3hydroxybutyrate-co-hydroxyvalerate (PHB-co-PHV), poly3hydroxybutyrate-co-hydroxyhexanoate (PHB-co-PHx).

Involvement of Terminase Complex in Herpes Simplex Virus Mature Virion Egress.

The life cycle of the Herpes simplex virus starts with attachment to the host cell, injection of the nucleocapsid into the cytoplasm, replication, transcription and viral protein production, and finally, the assembly of the mature virion nucleopcapsid. The assembled nucleocapsid exits the host nucleus and gains a tegument layer bound within a bilayer of membrane phospholipid. The packaged virion particle then exits the host cell. The interaction of the (Deoxyribonucleic acid) DNA packaging complex- terminase, present on the mature viral nucleocapsid, with other proteins involved in nuclear egress and cytoplasmic tegumentation has led to the proposal of the model by which the terminase complex may be involved in these two events. The role of terminase complex in Herpes Simplex Virus (HSV) genomic DNA encapsidation into the capsid is previously established, but the role of the terminase subunits post DNA packaging remains unclear. The current review provides a model by which the terminase complex may have a role to play in the events of nuclear egress and secondary envelopment.

Interplay between stress and immunity triggers herpes zoster infection in COVID-19 patients: a review.

Coronavirus disease 2019 (COVID-19) is a potential health threat in the highly mobile society of the world. There are also concerns regarding the occurrence of co-infections occurring in COVID-19 patients. Herpes zoster (HZ) is currently being reported as a co-infection in COVID-19 patients. It is a varicella-zoster virus induced viral infection affecting older and immunocompromised individuals. Reactivation of HZ infection in COVID-19 patients are emerging and the mechanism of reactivation is still unknown. The most convincing argument is that increased psychological and immunological stress leads to HZ in COVID-19 patients; this review justifies this argument.

Anti-Inflammatory Activity of Human Lens Crystallin Derived Peptide.

BACKGROUND: Inflammation has become the culmination point for several chronic diseases like skin diseases, asthma, neurological disorders, cancer, and cardiovascular disorders. Mini αA-crystallin peptide, identified from a highly conserved region of human lens protein αA-crystallin, is known to have a chaperone-like function; hence, it has generated interest in exploring the anti-inflammatory potential of the peptide. OBJECTIVE: The objective of the study was to evaluate the anti-inflammatory potential of mini αA chaperones using in vitro, ex-vivo, and in vivo models. METHODS: The peptide was tested for its phosphodiestarase4 B inhibition, anti-inflammatory and free radical scavenging abilities in HaCaT cells. Carbopol gel formulations with varying concentrations of mini αA-crystallin peptide and diclofenac sodium were prepared and optimized. Skin permeation studies of prepared formulations were carried out on excised abdominal skin of Wistar rat using a vertical type diffusion cell. Carrageenan induced rat paw oedema model was used for determining the anti-inflammatory potential of the peptide in prepared gel formulation with or without diclofenac sodium. RESULTS: The peptide exhibited appreciable free radical scavenging and weak PDE4B inhibition. Gel formulation with 1% Tween-80, 1% carbopol, and 10% ethanol showed better permeation compared to other formulations. The in vitro skin permeation studies revealed good improvement in permeation characteristics of diclofenac and peptide from the gels. The peptide was retained within the skin tissue, which is an ideal requirement for the delivery of an anti-inflammatory topical formulation. In preclinical anti-inflammatory studies, gel formulation containing mini αA-peptide and diclofenac sodium showed a significant decrease in paw volume compared to other combinations tested. CONCLUSION: The study revealed the additive effect in anti-inflammatory activity by combining mini-αA peptide and diclofenac sodium which effectively reduced the inflammation.

Is viral E6 oncoprotein a viable target? A critical analysis in the context of cervical cancer.

An understanding of the pathology of cervical cancer (CC) mediated by E6/E7 oncoproteins of high-risk human papillomavirus (HPV) was developed by late 80's. But if we look at the present scenario, not a single drug could be developed to inhibit these oncoproteins and in turn, be used specifically for the treatment of CC. The readers are advised not to presume the "viability of E6 protein" as mentioned in the title relates to just druggability of E6. The viability aspect will cover almost everything a researcher should know to develop E6 inhibitors until the preclinical stage. Herein, we have analysed the achievements and shortcomings of the scientific community in the last four decades in targeting HPV E6 against CC. Role of all HPV proteins has been briefly described for better perspective with a little detailed discussion of the role of E6. We have reviewed the articles from 1985 onward, reporting in vitro inhibition of E6. Recently, many computational studies have reported potent E6 inhibitors and these have also been reviewed. Subsequently, a critical analysis has been reported to cover the in vitro assay protocols and in vivo models to develop E6 inhibitors. A paragraph has been devoted to the role of public policy to fight CC employing vaccines and whether the vaccine against HPV has quenched the zeal to develop drugs against it. The review concludes with the challenges and the way forward.

siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection.

The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.

Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating.

Potential use of siRNA as therapeutic agent has elicited a great deal of interest. However, insufficient cellular uptake and poor stability limited its application in therapeutics. In our earlier study, we prepared PLGA nanoparticles for effective delivery of siRNA targeting Bcl-2 gene to block its expression. Purpose of the present study was to improve effectiveness of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 gene through chitosan coating. We prepared chitosan coated PLGA nanoparticles by using the double emulsion solvent diffusion (DESE) method. Characterization of prepared chitosan coated nanoformulation was done followed by cytotoxicity studies, expression studies and in vivo studies. Particle size of chitosan coated nanoparticles was found to be increased compared to PLGA nanoparticles from 244 to 319 nm. Surface charge of chitosan coated nanoparticles was found to be positive facilitating transfection of nanoformulation into cells. In vitro studies indicated increased transfection of nanoparticles resulting in effective silencing of Bcl-2. Marked apoptotic lesions were observed in nuclear staining studies. On comparison of the results from the present study with those of previous study, it was found that the extent of silencing of Bcl-2 gene by PLGA nanoformulation has improved significantly through chitosan coating. In vivo studies showed significant tumor regression in animals treated with chitosan coated PLGA nanoformulation of siRNA.

A nanoformulation of siRNA and its role in cancer therapy: in vitro and in vivo evaluation.

Overexpression of anti-apoptotic Bcl-2 is often observed in a wide variety of human cancers. It prevents the induction of apoptosis in neoplastic cells and contributes to resistance to chemotherapy. RNA interference has emerged as an efficient and selective technique for gene silencing. The potential to use small interfering RNA (siRNA) as a therapeutic agent for the treatment of cancer has elicited a great deal of interest. However, insufficient cellular uptake and poor stability have limited its therapeutic applications. The purpose of this study was to prepare chitosan nanoparticles via ionic gelation of chitosan by tripolyphosphate for effective delivery of siRNA to silence the anti-apoptotic Bcl-2 gene in neoplastic cells. Chitosan nanoparticles loaded with siRNA were in the size range 190 to 340 nm with a polydispersive index ranging from 0.04 to 0.2. They were able to completely bind with siRNA, provide protection against nuclease degradation, and enhance the transfection. Cell culture studies revealed that nanoparticles with entrapped siRNA could efficiently silence the antiapoptotic Bcl-2 gene. Studies on Swiss albino mice showed that siRNA could be effectively delivered through nanoparticles. There was significant decrease in the tumor volume. Blocking the expression of anti-apoptotic Bcl-2 can enhance the sensitivity of cancerous cells to anti-cancer drugs and the apoptosis rate. Therefore, nanoformulations with siRNA can be promoted as an adjuvant therapy in combination with anti-cancer drugs.

Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy.

The purpose of this research work was to prepare poly(d,l-lactide-co-glycolide) (PLGA) nanoparticles for delivery of siRNA (small interfering RNA) for silencing anti-apoptotic Bcl-2 gene in cancerous cells by using the double emulsion solvent diffusion (DESE) method. Overexpression of Bcl-2 is often seen in a wide variety of human cancers. This prevents the induction of programmed cell death (i.e., apoptosis) in cancerous cells. It is also reported that over-expression of Bcl-2 contributes to resistance in chemotherapy and inhibits the apoptosis induced by chemotherapeutic agents. Agents antagonizing the anti-apoptotic Bcl-2 protein have been shown to restore normal apoptotic processes in cancer cells. RNA interference (RNAi) has emerged as an efficient and selective technique for gene silencing, siRNA mediated gene silencing has been used in a wide variety of disease condition. PLGA nanoparticles were able to completely bind siRNA and to provide protection for siRNA against nuclease degradation. In vitro cell culture studies subsequently revealed that PLGA nanoparticles with adsorbed siRNA could efficiently silence the targeted anti-apoptotic Bcl-2 gene in mammalian cells. In vivo studies results showed that siRNA was effectively delivered through nanoparticles and there was significant decrease in the tumor volume.